About Tonix Pharmaceuticals
At Tonix, we are focused on identifying and developing candidates that have the promise to treat and prevent human disease and alleviate suffering. Through our own development, in-licensing, collaborations and acquisitions we are curating an innovative and effective portfolio that targets the relief of pain, and attenuates infection. Currently, our pipeline is primarily comprised of central nervous system (CNS), immunology and COVID-19 product candidates. We are progressing small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions through our CNS portfolio. Our immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer and autoimmune diseases.
Our lead CNS candidate, TNX-102 SL1 (sublingual formulation of cyclobenzaprine) is in mid-Phase 3 development for the management of fibromyalgia, a disorder characterized by chronic musculoskeletal pain, sleep deprivation, fatigue and mood changes. TNX-102 SL is also in clinical stages for PTSD, agitation in Alzheimer’s disease (AAD) and alcohol use disorder (AUD).
Tonix’s lead vaccine candidate, TNX-18002 , is a live replicating vaccine based on our proprietary synthetic horsepox viral vector platform to protect against COVID-19, primarily by eliciting a T cell response. Tonix reported positive efficacy data from animal studies of TNX-1800 in the first quarter of 2021. TNX-8012, our live horsepox viral vaccine for percutaneous administration, is in development to protect against smallpox and monkeypox.
1TNX-102 SL is an investigational new drug and has not been approved for any indication.
2TNX-1800 and TNX-801 are investigational new biologics and have not been approved for any indication.
Learn more about tonix